Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research
www.InvestorStemCell.com
Donate
Results 1 to 13 of 13
Like Tree53Likes
  • 19 Post By Peter Vaguely
  • 4 Post By ablidy
  • 2 Post By GMAN
  • 4 Post By stemdynasty
  • 1 Post By NOLAstemcell
  • 1 Post By RufusT
  • 5 Post By froggy
  • 4 Post By AZ geologist
  • 8 Post By stemdynasty
  • 3 Post By froggy
  • 2 Post By Waterbuglover

Thread: Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research

  1. #1
    Experience
    Points: 4,931, Level: 44
    Level completed: 91%, Points required for next Level: 19
    Overall activity: 7.0%
    Achievements:
    Tagger First Class1000 Experience PointsSocialVeteran
    Peter Vaguely's Avatar
    Join Date
    Apr 2011
    Posts
    338
    Location
    Milwaukee/Chicago
    Country: United States
    Likes Given: 505
    Likes Received: 852

    Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research

    Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research
    Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research - SFGate


    ACTC Mentioned

    "According to a new market report published by Transparency Market Research, “Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018,“ the market for stem cells was valued at USD 26.23 billion in 2011 and is expected to reach an estimated value of USD 119.51 billion in 2018, growing at a CAGR of 24.2% from 2012 to 2018."

    "The key players in stem cell research and technology include Advanced Cell Technology Inc., Stem Cell Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., and Cellartis Ab among others."
    stemedga, GMAN, k00ij and 16 others like this.

  2. #2
    Experience
    Points: 55,738, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 71.0%
    Achievements:
    SocialTagger First Class1 year registeredOverdrive50000 Experience Points
    ablidy's Avatar
    Join Date
    May 2011
    Posts
    1,850
    Location
    Northern California
    Country: United States
    Likes Given: 6407
    Likes Received: 7844
    wonder how much of that is going to be ACTc?
    Ask immunologic questions give molecular answers

  3. #3
    Experience
    Points: 42,599, Level: 100
    Level completed: 0%, Points required for next Level: 0
    Overall activity: 37.0%
    Achievements:
    SocialTagger First ClassOverdrive25000 Experience PointsVeteran
    Awards:
    Discussion Ender
    GMAN's Avatar
    Join Date
    Apr 2011
    Posts
    3,783
    Location
    NYC
    Country: United States
    Likes Given: 2437
    Likes Received: 5647
    The numbers just keep going up...
    ablidy and kokway like this.
    Great Minds Discuss Ideas. Average Minds Discuss Events. Small Minds Discuss People.


  4. #4
    stemdynasty
    stemdynasty's Avatar Guest
    Likes Given:
    Likes Received:
    That's a big number and makes the case for hedge funds to begin to look closer at reg med. It also makes for partnerships and takeovers. I simply can't fathom what the number would be if we were fully funded, had the manpower, the facilities, and the ability to fast track some of these CURES.

  5. #5
    Experience
    Points: 9,368, Level: 65
    Level completed: 6%, Points required for next Level: 282
    Overall activity: 7.0%
    Achievements:
    Tagger First Class1 year registered5000 Experience PointsSocial
    NOLAstemcell's Avatar
    Join Date
    Dec 2011
    Posts
    721
    Location
    New Orleans
    Country: United States
    Likes Given: 718
    Likes Received: 815
    Not that I was ever going to sell, but research likes this just confirms how devastated I would be if that $120B in the industry pans out, and I had no shares or equity to show for it because I was worried when one day in 2013 my stock was down 10%. Sign me up.
    WANT2RETIRE likes this.

  6. #6
    Experience
    Points: 3,209, Level: 35
    Level completed: 6%, Points required for next Level: 141
    Overall activity: 0%
    Achievements:
    1000 Experience Points1 year registeredTagger First Class
    RufusT's Avatar Partner Member
    Join Date
    Oct 2011
    Posts
    130
    Country: United States
    Likes Given: 95
    Likes Received: 219
    Peter, your old dancing Sierra Madre man makes me smile every time I see him. I've been practicing that jig. Now I just hope the treasure changes us all for the good!
    Last edited by RufusT; 08-20-2013 at 06:17 PM.
    kokway likes this.

  7. #7
    Experience
    Points: 10,696, Level: 68
    Level completed: 62%, Points required for next Level: 154
    Overall activity: 34.0%
    Achievements:
    Tagger First Class1 year registered10000 Experience Points
    froggy's Avatar
    Join Date
    Sep 2012
    Posts
    508
    Location
    cleveland, ohio
    Country: United States
    Likes Given: 2462
    Likes Received: 1463
    So we are the leader but in spite of that what if we only got 20% of the market? 20% of $120b is 24b. On revenue of around 10b novartis has a market cap of 200b. A multiple of twenty times. Roche's multiple is also around 20. So our multiple at 24b would be over 400b. Pretty freaky stuff.QUOTE=Peter Vaguely;168948]Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research
    Stem Cells Market Will Reach USD 119.51 Billion in 2018: Transparency Market Research - SFGate


    ACTC Mentioned

    "According to a new market report published by Transparency Market Research, “Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018,“ the market for stem cells was valued at USD 26.23 billion in 2011 and is expected to reach an estimated value of USD 119.51 billion in 2018, growing at a CAGR of 24.2% from 2012 to 2018."

    "The key players in stem cell research and technology include Advanced Cell Technology Inc., Stem Cell Technologies Inc., Cellular Engineering Technologies Inc., BioTime Inc., and Cellartis Ab among others."[/QUOTE]

  8. #8
    Experience
    Points: 18,146, Level: 85
    Level completed: 60%, Points required for next Level: 204
    Overall activity: 10.0%
    Achievements:
    SocialTagger First Class1 year registered10000 Experience Points
    AZ geologist's Avatar
    Join Date
    Jun 2011
    Posts
    1,045
    Country: United States
    Likes Given: 1074
    Likes Received: 3852
    Quote Originally Posted by froggy View Post
    So we are the leader but in spite of that what if we only got 20% of the market? 20% of $120b is 24b. On revenue of around 10b novartis has a market cap of 200b. A multiple of twenty times. Roche's multiple is also around 20. So our multiple at 24b would be over 400b. Pretty freaky stuff.
    And to take that analysis one step further, based on today's share structure, that comes out to a pre-R/S price of ~$38/share. Owners with fewer than ~27000 shares today (again pre-R/S) would end up millionaires. Not a bad return for a stock that's six and a half cents today.

    EDIT: Updated figures to reflect Stargazer's more conservative Google Finance-derived numbers. Still looks great.
    Last edited by AZ geologist; 08-20-2013 at 07:57 PM.


  9. #9
    Experience
    Points: 2,945, Level: 33
    Level completed: 30%, Points required for next Level: 105
    Overall activity: 0%
    Achievements:
    1000 Experience PointsTagger First ClassSocialVeteran
    Stargazer's Avatar
    Join Date
    Feb 2011
    Posts
    63
    Location
    Vancouver, British Columbia
    Country: Canada
    Likes Given: 171
    Likes Received: 121
    Quote Originally Posted by froggy View Post
    On revenue of around 10b novartis has a market cap of 200b.
    Froggy, Google Finance states that Novartis' 2012 year end revenue was 57.5B and the current mcap is 183B so the mcap/sales multiple is 3.2 and not 20. Also the mcap/sales multiple for Roche is 4.5 and not 20.

    So using your rationale if ACTC's achieves a revenue of 24B, its mcap would be in the range of 100B (using the average of NVS and Roche multiples)

  10. #10
    stemdynasty
    stemdynasty's Avatar Guest
    Likes Given:
    Likes Received:
    Our market cap is around 155 million today. This isn't getting in at the ground floor, more like bargain basement. Think in terms of generational wealth. We are the epitomy of true investors..... Warren Buffett style. Recognize a great company, buy on sale, load up, and hold. Let others chase it when they figure it out what you already know. Stay the course.

  11. #11
    Experience
    Points: 10,696, Level: 68
    Level completed: 62%, Points required for next Level: 154
    Overall activity: 34.0%
    Achievements:
    Tagger First Class1 year registered10000 Experience Points
    froggy's Avatar
    Join Date
    Sep 2012
    Posts
    508
    Location
    cleveland, ohio
    Country: United States
    Likes Given: 2462
    Likes Received: 1463
    I was looking at PE ratios so you are correct. the novartis PE is 19.6 and the Roche PE is 18.6. But it does appear that at least with the eye program that $100 cost per dose will get us a very significant earnings per cent of revenue.
    Quote Originally Posted by Stargazer View Post
    Froggy, Google Finance states that Novartis' 2012 year end revenue was 57.5B and the current mcap is 183B so the mcap/sales multiple is 3.2 and not 20. Also the mcap/sales multiple for Roche is 4.5 and not 20.

    So using your rationale if ACTC's achieves a revenue of 24B, its mcap would be in the range of 100B (using the average of NVS and Roche multiples)
    Stargazer, saxxie and fred1947dy like this.

  12. #12
    Experience
    Points: 2,388, Level: 29
    Level completed: 59%, Points required for next Level: 62
    Overall activity: 7.0%
    Achievements:
    1000 Experience PointsVeteran
    Waterbuglover's Avatar
    Join Date
    Apr 2011
    Posts
    29
    Location
    Stevenson, Washington
    Country: United States
    Likes Given: 3
    Likes Received: 39
    Who’s the first company listed?

    If ACTC treats 1,000,000 people at $10,000/eye a year they get $20 billion of the $120 billion market.

    Their cost /eye $100 ( 99% profit margin).

    30,000,000 million people have AMD. After issuing new shares. Their profit will only be:

    3.75 billion shares/ $19.8 billion = $5.28/share profit. What do you think the share price will be in 5 years?

    Must be drinking way to much Koolaid.
    saxxie and fred1947dy like this.

  13. #13
    stemdynasty
    stemdynasty's Avatar Guest
    Likes Given:
    Likes Received:
    Ask Dr Knoepfler that seems to have a functioning crystal ball into our future.